Matches 1 - 50 out of 184 1 2 3 4 >


Match Document Document Title
US20110086796 METHODS FOR PREDICTING THE DEVELOPMENT AND RESOLUTION OF ACUTE RESPIRATORY DISTRESS SYNDROME  
The subject invention features methods for predicting whether a subject at risk of developing Acute Respiratory Distress Syndrome (ARDS) will develop ARDS by determining the amount of elafin...
US20150079105 TREATMENT OF ACUTE INFLAMMATION IN THE RESPIRATORY TRACT  
This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of acute inflammation of the respiratory tract, especially...
US20110152171 HISTAMINE BINDING PROTEIN  
The invention relates to histamine binding proteins. The invention also relates to the use of such histamine binding proteins in the treatment and prevention of diseases.
US20150196619 EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT  
The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus...
US20120283167 EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT  
The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus...
US20110256130 METHODS OF TREATING INFLAMMATORY DISORDERS  
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
US20100310660 DRY POWDER MICROPARTICLES FOR PULMONARY DELIVERY  
The invention provides a dry powder microparticle for pulmonary delivery, which comprises at least one nanoparticle in the form of liposome or micelle wherein the nanopaparticle encapsulates one...
US20110189104 SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY  
Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are...
US20110293727 CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME  
Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a...
US20130184198 Pulmonary Surfactant Formulations  
Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl...
US20110262386 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding...
US20070244045 Treatment of Acute Respiratory Distress Syndrome  
Patients suffering from acute respiratory distress syndrome or acute lung injury are treated by administering to the patients a therapeutically effective dosage of a surfactant that includes SP-B...
US20140142021 RECONSTITUTED PULMONARY SURFACTANTS  
The present invention is directed to a reconstituted surfactant comprising a phospholipid mixture, and a combination of particular analogues of the native surfactant protein SP-C with analogues of...
US20140037634 REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF  
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ╬▒CD3 proliferation of T cells in vitro. A...
US20130261047 METHODS AND COMPOSITIONS FOR THE REDUCTION OF NEUTROPHIL INFLUX AND THE TREATMENT OF BRONCHOPULMONARY DISPLASIA, RESPIRATORY DISTRESS SYNDROME, CHRONIC LUNG DISEASE, PULMONARY FIBROSIS, ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory...
US20110183887 METHODS AND COMPOSITIONS FOR THE REDUCTION OF NEUTROPHIL INFLUX AND THE TREATMENT OF BRONCHOPULMONARY DISPLASIA, RESPIRATORY DISTRESS SYNDROME, CHRONIC LUNG DISEASE, PULMONARY FIBROSIS, ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory...
US20120010126 RECOMBINANT SURFACTANT PROTEIN D COMPOSITIONS AND METHODS OF USE THEREOF  
We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual...
US20110003733 RECONSTITUTED SURFACTANT COMPOSITION CONTAINING ANALOGS OF SURFACTANT PROTEIN B (SP-B) AND SURFACTANT PROTEIN C (SP-C)  
Reconstituted pulmonary surfactants comprising a lipid carrier, a combination of polypeptide analog of the native surfactant protein SP-C with a particular polypeptide analog of the native...
US20100311642 USE OF V2 RECEPTOR ANTAGONISTS IN COMBINATION WITH VASO PRESSINERGIC AGNOSTS  
The combination of vasopressin V2 receptor antagonists and vasopressin receptor agonists (selective or non-selective) is described, including pharmaceutical compositions, including kits, for...
US20140322226 ACTH FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME  
Provided herein are methods of treatment of acute respiratory distress syndrome comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof,...
US20130085096 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO  
The present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, in vitro or in vivo, with a hedgehog...
US20110195893 USE OF APOLIPOPROTEINS TO DECREASE INFLAMMATION  
The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory...
US20120289452 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NECROSIS  
A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells.
US20110236367 RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES  
The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present...
US20140286906 USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES  
The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or...
US20140127232 DETECTING, PREVENTING, AND TREATING BRONCHOPULMONARY DYSPLASIA  
Provided herein are methods for preventing or treating bronchopulmonary dysplasia (BPD) in a subject. The methods comprise identifying connective tissue mast cells (CTMCs) in a subject and...
US20130079275 RECONSTITUTED SURFACTANTS HAVING IMPROVED PROPERTIES  
Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the...
US20130005644 CYCLIC AGONISTS AND ANTAGONISTS OF C5A RECEPTORS AND G PROTEIN-COUPLED RECEPTORS  
The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by...
US20150141322 THERAPEUTIC AGENT, TREATMENT METHOD AND INSPECTION METHOD FOR DISEASES CAUSED BY ACTIVATION OR NEUTROPHILS  
The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a...
US20150087576 COMPOSITIONS ASSOCIATED WITH AND METHODS OF MANAGING NEUTROPHIL MOVEMENT USING SERUM AMYLOID P (SAP)  
The disclosure also relates to a method of reducing the number of neutrophils in a body region by administering a Serum Amyloid P (SAP) composition in an amount and for a time sufficient to...
US20130288950 USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS  
The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction...
US20110201543 USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS  
The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction...
US20120164123 METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN  
Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine...
US20140341876 METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN  
Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a defensin polypeptide including at least one arginine residue susceptible to...
US20150004165 SECRETED PROTEINS  
The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and...
US20140056906 SECRETED PROTEINS  
The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and...
US20110206668 METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY  
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The...
US20050250684 Method for reducing morbidity and mortality in critically ill patients  
This invention relates to a novel method of reducing the mortality and morbidity in critically ill patients which comprises administering to the patients an effective amount of FGF-19.
US20120277142 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME  
Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor...
US20110053831 COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL DISORDERS ASSOCIATED WITH THEREWITH  
Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the...
US20130064835 RAGE REGULATES ROCK ACTIVITY IN CARDIOVASCULAR DISEASE  
A method is provided for treating a RAGE-related disorder in a subject afflicted therewith comprising administering to the subject a therapeutically effective amount of an antagonist of...
US20130237472 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-I POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME  
The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof....
US20080045449 Novel Lipid Mixtures For Synthetic Surfactants  
The present invention provides novel lipid mixtures for synthetic surfactants. In particular, the invention provides a specific lipid mixture containing a specific amount of polyunsaturated...
US20110212051 VARIANTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR AND USE THEREOF  
Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer,...
US20110142837 Method Of Treating Acute Respiratory Distress Syndrome  
Methods for treating and/or alleviating acute respiratory distress syndrome in an individual diagnosed with or at risk of developing acute respiratory distress syndrome are disclosed. The methods...
US20120135916 MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE  
Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition,...
US20150031599 HEMOGLOBIN COMPOSITIONS  
The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto...
US20140005096 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, are peptides for use in inhibiting the interactions of PF4 and RANTES. Further disclosed herein, are methods for treating an inflammatory disease,...
US20060263302 Systemic oxygenation via gastric perfusion with perfluorocarbon (PFC)  
The present invention is based on the discovery that an increase in systemic oxygenation can be achieved by gastric perfusion of an oxygenated liquid, e.g., perfluorocarbon. Accordingly, the...
US20120321701 ANG-(1-7) RECEPTOR AGONIST  
The application provides Ang-(1-7) receptor agonist peptides and their use for treating acute lung injury.

Matches 1 - 50 out of 184 1 2 3 4 >